Table of Contents
J. Clin. Med., Volume 6, Issue 8 (August 2017)
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Cover Story Cardiovascular disease is predicted to account for >23 million by 2030. There is now consensus that [...] Read more. Cardiovascular disease is predicted to account for >23 million by 2030. There is now consensus that dyslipidaemia induces atherosclerosis. Statins have become the cornerstone for management of dyslipidaemia and have a very good safety profile. Nevertheless, potential risk of an adverse event must be considered when using statin therapy for patients. Statin-associated muscle disease (SAMS) is the most common reason for discontinuation of therapy. Reported incidence varies, ranging between 5% and 29%. Milder disease is common. The more serious form, rhabdomyolysis is rarer, with an incidence of roughly 1 in 10000. The pathophysiology of SAMS is not yet fully understood. Although literature points towards statin-induced mitochondrial dysfunction, exact mechanism is not yet elucidated. This paper details some of the different aetiological hypotheses related to mitochondrial dysfunction put forward in the literature.